Titre :

Efficacy and safety of infliximab retreatment: in crohn's disease:a multicentre, prospective, observational cohort (regain) study.

Auteur(s) :

Boschetti, Gilles [Auteur]
Centre International de Recherche en Infectiologie [CIRI]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Laharie, David [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Roblin, Xavier [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Aubourg, Alexandre [Auteur]
CHU Trousseau [Tours]
Bourreille, Arnaud [Auteur]
Institut des Maladies de l'Appareil Digestif
Zallot, Camille [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Hebuterne, Xavier [Auteur]
Hôpital l'Archet
Buisson, Anthony [Auteur]
CHU Clermont-Ferrand
Grimaud, Jean-Charles [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Bouhnik, Yoram [Auteur]
Hôpital Beaujon [AP-HP]
Allez, Matthieu [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Altwegg, Romain [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Viennot, Stéphanie [Auteur]
CHU Caen
Vuitton, Lucine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Carbonnel, Franck [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Paul, Stéphane [Auteur]
Physiopathologie et biothérapies des infections muqueuses [CIRI] [CIRI-GIMAP]
Desseaux, Kristell [Auteur]
Lambert, Jérome [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]

Titre de la revue :

The American Journal of Gastroenterology

Nom court de la revue :

Am J Gastroenterol

Numéro :

117

Pagination :

1482-1490

Date de publication :

2022-08-18

ISSN :

1572-0241

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

INTRODUCTION: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance. METHODS: We conducted ...
Lire la suite >INTRODUCTION: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance. METHODS: We conducted a prospective multicenter observational cohort study including adult patients with clinically (CD Activity Index >150) and objectively active luminal CD in whom IFX was reintroduced after at least 6 months of discontinuation. The reasons for the initial discontinuation could be a secondary loss of response or IFX intolerance. The reintroduction schedule included 3 IFX infusions at weeks 0, 4, and 8, after a systematic premedication. The primary end point was the efficacy of IFX retreatment at week 26 defined by a CD Activity Index of <150 in the absence of IFX discontinuation or use of corticosteroids, surgery, or other biologic. RESULTS: At week 26, 24 patients (35%) among the 69 analyzed reached the primary end point. No significant difference was observed between rates of clinical remission at week 26 in patients with prior LOR (n = 48) and those with IFX intolerance (n = 21) (35% and 33%, P = 0.87, respectively). Thirty-two acute infusion reactions were recorded in 27 patients, leading to withdrawal of IFX in 20 patients. No pharmacokinetic characteristic at baseline but detection of positive anti-drug antibodies at week 4 was predictive of IFX failure or infusion reaction at week 26. DISCUSSION: In this first prospective cohort study, IFX retreatment was safe and effective in one-third of the patients with CD, regardless the reason of prior discontinuation. Early detection of anti-drug antibodies can predict subsequent IFX reintroduction failure and infusion reactions.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T00:51:00Z
2024-02-28T07:33:33Z